Skip to main content Accessibility help

Second generation antipsychotics: evolution of scientific knowledge or uncovering fraud

  • R. Rosenheck (a1)
Corresponding author
Address for correspondence: Professor Robert Rosenheck, VA Connecticut Health Care System, 950 Campbell Avenue, Building 35, West Haven, CT 06516, USA. (Email:
Hide All
Almashat, S, Preston, C, Waterman, T, Wolfe, S, Public Citizen's Health Research Group (2010). Rapidly Increasing Criminal and Civil Monetary Penalties Against the Pharmaceutical Industry: 1991 to 2010. Retrieved 12 October 2011 from
Breier, A (2011). Anxiety disorders and antipsychotic drugs: A pressing need for more research. American Journal of Psychiatry 168, 10121014.
Berenson, A (2006). Eli Lilly Said to Play Down Risk of Top Pill. New York Times, 17 December 2006. Retrieved 12 October 2011 from
Business Week (2012a). Arkansas judge fines J&J $1.1B in Risperdal case. Business Week, April 2012. Retrieved 30 October 2011 from
Business Week (2012b). J&J Said to Agree to $2.2 Billion Drug Marketing Accord. Business Week, June 2012. Retrieved 30 October 2011 from
Comer, JS, Mojtabai, R, Olfson, M (2011). National trends in the antipsychotic treatment of psychiatric outpatients with anxiety disorders. American Journal of Psychiatry 168, 10571065
Hausman, K (2009). Industry-supported symposia to be phased out. Psychiatry News 44, 4.
Leslie, D & Rosenheck, RA (2012). Off-label use of antipsychotic medications in Medicaid. American Journal of Managed Care 18, e109e117.
Leslie, DL, Mohamed, S, Rosenheck, RA (2009). Off-label use of antipsychotic medications in the Department of Veterans Affairs. Psychiatric Services 60, 11751181.
Lewis, DA, Michels, R, Pine, DS, Schultz, SK, Tamminga, CA, Freedman, R (2006). Conflict of interest. American Journal of Psychiatry 163, 571573.
Rosenheck, RA (2005). The growth of psychopharmacology in the 1990s: evidence-based practice or irrational exuberance. International Journal of Law and Psychiatry 28, 467483.
Rosenheck, R, Perlick, D, Bingham, S, Liu-Mares, W, Collins, J, Warren, S, Leslie, D, Allan, E, Campbell, EC, Caroff, S, Corwin, J, Davis, L, Douyon, R, Dunn, L, Evans, D, Frecska, E, Grabowski, J, Graeber, D, Herz, L, Kwon, K, Lawson, W, Mena, F, Sheikh, J, Smelson, D, Smith-Gamble, V; Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine (2003). Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. Journal of the American Medical Association 290, 26932702.
Tollefson, GD, Beasley, CM Jr, Tran, PV, Street, JS, Krueger, JA, Tamura, RN, Graffeo, KA, Thieme, ME (1997). Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry 154, 457465.
US Department of Justice (2009). Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-label Promotion of Zyprexa. Retrieved 30 October 2012 from
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology and Psychiatric Sciences
  • ISSN: 2045-7960
  • EISSN: 2045-7979
  • URL: /core/journals/epidemiology-and-psychiatric-sciences
Please enter your name
Please enter a valid email address
Who would you like to send this to? *



Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed